Vumerity™ Oral Capsules Approved by the FDA for Adults with Relapsing Forms of MS, Including Active SPMS

On October 30, 2019, Biogen Inc. and Alkermes plc announced the United States Food and Drug Administration (FDA) approval of Vumerity (diroximel fumarate) oral capsules to treat adults with relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS).

Read News Article

MS Research Mythbusting

Featuring Mitzi Joi Williams, MD While multiple sclerosis affects all races and ethnicities, minority populations may bear an unequal burden from the disease, including a higher risk of aggressive disease […]

Read News Article

MSAA’s 50th Anniversary

Founded in 1970, MSAA is marking its 50th anniversary in 2020 as a nonprofit organization dedicated to supporting the multiple sclerosis community and Improving Lives Today through vital services and […]

Read News Article